Cristina R Antonescu Selected Research

Creatinine

1/2022	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.
1/2018	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cristina R Antonescu Research Topics

Disease

176	Neoplasms (Cancer) 12/2022 - 01/2002
64	Sarcoma (Soft Tissue Sarcoma) 09/2022 - 08/2002
50	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022 - 08/2002
17	Carcinoma (Carcinomatosis) 12/2021 - 07/2011
10	Neurofibrosarcoma (MPNST) 01/2022 - 07/2009
9	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2002
9	Hemangiosarcoma (Angiosarcoma) 01/2022 - 05/2005
9	Synovial Sarcoma (Synovioma) 01/2021 - 02/2002
8	Leiomyosarcoma 01/2022 - 12/2012
8	Melanoma (Melanoma, Malignant) 01/2018 - 05/2003
8	Necrosis 01/2018 - 03/2005
8	Liposarcoma 07/2016 - 03/2005
7	Carcinogenesis 12/2022 - 03/2004
7	Ewing Sarcoma (Sarcoma, Ewing) 01/2022 - 10/2014
6	Disease Progression 01/2022 - 05/2005
5	Perivascular Epithelioid Cell Neoplasms 01/2022 - 02/2010
5	Genetic Translocation (Chromosomal Translocation) 11/2020 - 08/2002
4	Mesothelioma 10/2022 - 11/2020
4	Endometrial Stromal Sarcoma 01/2022 - 01/2021
4	Osteosarcoma (Osteogenic Sarcoma) 01/2019 - 03/2005
4	Neurofibromatosis 1 (Neurofibromatosis Type I) 04/2016 - 04/2005
3	Anemia 01/2022 - 01/2019
3	Adenocarcinoma 01/2021 - 01/2015
3	Chondrosarcoma 01/2020 - 03/2009
3	Rhabdomyosarcoma 01/2019 - 01/2016
3	Dermatofibrosarcoma 01/2018 - 08/2002
3	Clear Cell Sarcoma 04/2017 - 09/2006
2	Adamantinoma 09/2022 - 09/2015
2	Glomus Tumor (Glomus Tumors) 01/2022 - 01/2020
2	Exanthema (Rash) 01/2022 - 01/2022
2	Hypophosphatemia 01/2022 - 01/2022
2	Edema (Dropsy) 01/2022 - 01/2019
2	Salivary Gland Neoplasms (Salivary Gland Cancer) 10/2021 - 10/2017
2	Bone Resorption 04/2021 - 03/2005
2	Malignant Mesothelioma 01/2021 - 07/2017
2	Myoepithelioma 11/2020 - 10/2019
2	Angiomatoid Fibrous Histiocytoma 11/2020 - 04/2017
2	Fibrosarcoma 10/2020 - 01/2017
2	Myopericytoma 01/2020 - 11/2013
2	Fever (Fevers) 01/2019 - 01/2018

Drug/Important Bio-Agent (IBA)

43	RNA (Ribonucleic Acid)IBA 11/2022 - 05/2003
43	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 08/2002
26	Phosphotransferases (Kinase)IBA 01/2022 - 10/2005
19	DesminIBA 11/2022 - 04/2005
19	Keratins (Keratin)IBA 09/2022 - 11/2002
18	Biological ProductsIBA 01/2022 - 01/2002
17	Proteins (Proteins, Gene)FDA Link 12/2022 - 11/2002
17	S100 Proteins (S 100 Protein)IBA 01/2022 - 10/2003
17	Transcription Factors (Transcription Factor)IBA 01/2021 - 11/2002
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2007
8	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2005
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2017 - 05/2003
6	Cyclin D1IBA 01/2022 - 12/2017
6	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 08/2011
6	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2013 - 04/2005
6	Sunitinib (Sutent)FDA Link 05/2012 - 10/2006
5	Pharmaceutical PreparationsIBA 01/2021 - 07/2007
5	Messenger RNA (mRNA)IBA 01/2020 - 12/2016
5	CollagenIBA 12/2018 - 08/2002
5	AntigensIBA 03/2009 - 02/2002
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2005
4	SynaptophysinIBA 01/2022 - 06/2015
4	Estrogen ReceptorsIBA 01/2022 - 01/2018
4	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 01/2018
4	tyrosine receptor (receptor, tyrosine)IBA 10/2020 - 02/2008
4	Mucin-1 (CA 15-3 Antigen)IBA 12/2019 - 12/2002
4	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 08/2007
4	Complementary DNA (cDNA)IBA 06/2013 - 11/2002
4	Sirolimus (Rapamycin)FDA Link 04/2013 - 02/2010
4	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2013 - 02/2002
3	AsbestosIBA 10/2022 - 07/2017
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 03/2015
3	Polycomb Repressive Complex 2IBA 01/2022 - 04/2016
3	binimetinibIBA 01/2022 - 03/2015
3	MART-1 AntigenIBA 01/2022 - 10/2018
3	Calmodulin-Binding Proteins (Caldesmon)IBA 10/2021 - 01/2018
3	Anaplastic Lymphoma KinaseIBA 01/2021 - 01/2016
3	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 11/2020 - 07/2015
3	Cathepsin KIBA 11/2019 - 01/2016
3	palbociclibIBA 01/2017 - 06/2013
3	Monoclonal AntibodiesIBA 12/2016 - 02/2002
3	AntibodiesIBA 02/2007 - 03/2004
2	NivolumabIBA 01/2022 - 01/2018
2	CreatinineIBA 01/2022 - 01/2018
2	trans-sodium crocetinate (crocetin)IBA 01/2022 - 04/2013
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 01/2018
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
2	ChromograninsIBA 11/2021 - 11/2021
2	ChromatinIBA 01/2021 - 01/2019
2	SMARCB1 ProteinIBA 10/2020 - 06/2014
2	B7-H1 AntigenIBA 01/2020 - 01/2017
2	Proto-Oncogene Proteins c-etsIBA 01/2020 - 07/2014
2	ParaffinIBA 01/2020 - 04/2005
2	Protein Kinases (Protein Kinase)IBA 10/2019 - 01/2019
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2019 - 01/2018

Therapy/Procedure

57	Therapeutics 01/2022 - 08/2002
19	Drug Therapy (Chemotherapy) 06/2020 - 11/2004
7	Radiotherapy 06/2018 - 12/2011
5	Immunotherapy 01/2019 - 02/2002
3	Aftercare (After-Treatment) 02/2009 - 12/2004